Urovant’s Gemtesa (vibegron) was the subject of two positive presentations at the Annual Meeting of the American Urological Association (AUA2021). The first explained that vibegron is effective in patients with ‘dry’ overactive bladder (OAB) based on a post-hoc analysis of the pivotal EMPOWUR trial. The second presentation explained that vibegron had a negligible impact on ambulatory…